Related Experiment Video
Updated: Feb 17, 2026
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Molecular and Microstructural MRI of Neuroinflammation in Alzheimer's Disease
Banafsheh Baniasadipour1, Fariba Bagheri1, Farzane Hendudari2
1Department of Radiology Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Introduction:
Alzheimer's disease (AD) is a leading cause of cognitive decline in older adults, often diagnosed late when pathology and symptoms are established, reducing treatment effectiveness. Both AD and mild cognitive impairment (MCI) trigger neuroinflammation, leading to molecular and microstructural changes, including oxidative stress, mitochondrial dysfunction, glial activation, synaptic and neurotransmitter disturbances, myelin degradation, and white matter dysfunction. The blood-brain barrier (BBB) is also compromised.
Methods:
Advanced magnetic resonance imaging (MRI) techniques, such as magnetic resonance spectroscopy (MRS), diffusion tensor imaging (DTI), diffusion kurtosis imaging (DKI), magnetization- transfer imaging (MTI), chemical exchange saturation transfer (CEST), contrast-enhanced MRI (CE-MRI), and arterial spin labeling (ASL), offer promise for the early detection of Alzheimer's disease (AD)-related molecular and microstructural changes.
Results:
Based on recent studies, advanced MRI modalities-including magnetic resonance spectroscopy, diffusion imaging, contrast-enhanced imaging, and chemical shift imaging-can highlight metabolic dysfunction, white matter degradation, microstructural disruption, blood-brain barrier dysfunction, cerebral hypoperfusion, vascular dysfunction, and pH alterations caused by neuroinflammation in Alzheimer's patients.
Discussion:
The integration of advanced MRI modalities into clinical practice could improve the diagnosis and management of Alzheimer's disease (AD). Magnetic resonance spectroscopy and diffusion imaging can identify metabolic and microstructural changes years before brain atrophy occurs, aiding professionals in the early detection of AD. Additionally, perfusion imaging and magnetization transfer imaging can help distinguish between Alzheimer's disease, frontotemporal dementia (FTD), and vascular dementia. Finally, contrast-enhanced MRI can monitor the integrity of the blood-brain barrier to evaluate responses to drug treatments.
Conclusion:
Despite challenges, such as longer scan times and limited specificity, advanced MRIbased approaches are at the forefront of identifying reliable biomarkers for early detection of Alzheimer's disease and determining optimal management and treatment strategies.
Insights
Advanced MRI techniques can detect Alzheimer's disease (AD) and mild cognitive impairment (MCI) early by identifying neuroinflammation and microstructural changes. These methods aid in diagnosis, differentiate dementia types, and monitor treatment effectiveness for better patient outcomes.
Area of Science:
- Neuroimaging
- Neurology
- Biomarker Discovery
Background:
- Alzheimer's disease (AD) and mild cognitive impairment (MCI) lead to cognitive decline, often diagnosed late.
- Neuroinflammation in AD/MCI causes molecular, microstructural, and blood-brain barrier (BBB) changes.
Purpose of the Study:
- To explore the potential of advanced magnetic resonance imaging (MRI) techniques for early AD detection.
- To identify reliable biomarkers for AD diagnosis and management.
Main Methods:
- Utilized advanced MRI techniques: magnetic resonance spectroscopy (MRS), diffusion tensor imaging (DTI), diffusion kurtosis imaging (DKI), magnetization-transfer imaging (MTI), chemical exchange saturation transfer (CEST), contrast-enhanced MRI (CE-MRI), and arterial spin labeling (ASL).
Main Results:
- Advanced MRI modalities detect metabolic dysfunction, white matter degradation, microstructural disruption, BBB dysfunction, and hypoperfusion in AD patients.
- Techniques like MRS and diffusion imaging identify changes years before atrophy.
- Perfusion and MTI imaging differentiate AD from FTD and vascular dementia.
Conclusions:
- Integrating advanced MRI into clinical practice can improve AD diagnosis and management.
- MRI offers reliable biomarkers for early AD detection and treatment monitoring.
- Despite challenges, advanced MRI is crucial for identifying AD biomarkers and optimizing treatment.
